Therefore, combinatorial treatments compensating also for loss of function mutations (e.g. CDK4/6 inhibition for homozygous CDKN2A/B deletion) and targeted elimination of glioma stem cells before clonal evolution occur, could increase treatment success in these tumor entities. The gene discussed is CDKN2A; the disease is neoplasm.